Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15–34 years of age: A nationwide register-based study
Jenny Niemeyer Hultstrand(Uppsala University), Inger Sundström Poromaa(Uppsala University), Helena Kopp Kallner(Danderyds sjukhus), Kristina Gemzell‐Danielsson(Karolinska University Hospital), Per Wikman(Uppsala University), Henrik Lindman(Uppsala University)
Cited by 45
Related Papers
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial
|The Lancet|2000|343
Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers
|Scientific Reports|2017|275
Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [<sup>68</sup>Ga]ABY-025 Affibody PET/CT
|Theranostics|2015|269
First-in-Human Molecular Imaging of HER2 Expression in Breast Cancer Metastases Using the <sup>111</sup>In-ABY-025 Affibody Molecule
|Journal of Nuclear Medicine|2014|260